ugc approved journal list IJRTI Research Journal
International Journal for Research Trends and Innovation
An International Open Access Journal | UGC and ISSN Approved
Impact Factor: 4.87

Call For Paper

Issue: December 2017

Volume 2 | Issue 12

Impact Factor: 4.87

Submit Paper Online

Click Here For more Details

For Authors

Forms / Download

Editorial Board

Subscribe IJRTI

Facts & Figure

Impact Factor : 4.87

Issue per Year : 12

Volume Published : 2

Issue Published : 19

Article Submitted : 639

Article Published : 405

Total Authors : 1152

Total Reviewer : 499

Total Pages : 14

Total Countries : 8

Visitor Counter


Indexing Partner

Published Paper Details
Paper Title: Emodin as an alternative to Pazopanib aided inhibition of tumor angiogenesis: an explicit molecular docking analysis
Authors Name: Taseem A. Mokhdomi , Shoiab Bukhari , Asif Amin , Qazi Danish , Sajad H. Wani
Unique Id: IJRTI1712003
Published In: Volume 2 Issue 12, December-2017
Abstract: Fibroblast growth factor receptor-2 (FGFR-2) primarily regulating mitogenesis and differentiation, is considered as a major prognostic biomarker as well as a therapeutic target in human solid tumors. Most of the therapeutic drugs have been designed to target its catalytic domain which inhibit tyrosine phosphorylation of its kinase domain and hence block its downstream signaling. In this study, we analyzed selected drug-leads from western himalayan chemiome for their ability to bind and selectively inhibit FGFR-2 activation. Structure based bioinformatics were employed to select lead compound(s) targeting catalytic domain of FGFR-2. Out of 120 compounds from selective western himalayan chemiome library, Emodin showed best binding-affinity with catalytic domain of FGFR-2 blocking ATP binding. The binding efficiency of Emodin was comparable to Pazopanib, FDA approved Tyrosine Kinase Inhibitor which is a potent and selective inhibitor of FGFR-2 currently in clinical trials. To further corroborate these findings, we evaluated binding efficiency of Emodin in 2 constitutively active mutants of FGFR-2 viz N549T and E565A. Emodin efficiently blocked ATP pocket in their respective catalytic domain comparable to Pazopanib. The results in this study thus not only project Emodin as a lead molecule to overcome FGFR-2 mediated tumor mitogenesis but also demonstrates its potential as a tyrosine kinase inhibitor to overcome tumor angiogenesis.
Keywords: FGFR-2; Tyrosine Kinase Inhibitors; Pazopanib; Emodin; Molecular Docking Simulation.
Cite Article: "Emodin as an alternative to Pazopanib aided inhibition of tumor angiogenesis: an explicit molecular docking analysis", International Journal of Science & Engineering Development Research (www.ijrti.org), ISSN:2455-2631, Vol.2, Issue 12, page no.14 - 17, December-2017, Available :http://www.ijrti.org/papers/IJRTI1712003.pdf
Downloads: 00015
Publication Details: Published Paper ID: IJRTI1712003
Registration ID:170589
Published In: Volume 2 Issue 12, December-2017
DOI (Digital Object Identifier):
ISSN Number: 2456 - 3315
Share Article:

Click Here to Download This Article

Article Preview



Major Indexing from www.ijrti.org
Google Scholar ResearcherID Thomson Reuters Mendeley : reference manager Academia.edu
arXiv.org : cornell university library Research Gate CiteSeerX DOAJ : Directory of Open Access Journals
DRJI Index Copernicus International Scribd DocStoc

ISSN Details

DOI (A digital object identifier)



Providing A digital object identifier by DOI
How to GET DOI and Hard Copy Related

RMS

Conference Proposal

Latest News / Updates

Open Access License Policy

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Creative Commons License This material is Open Knowledge This material is Open Data This material is Open Content

Important Details

Social Media

Untitled Document